- Acadia Pharmaceuticals Inc ACAD reported a Q4 EPS loss of $(0.26), missing the consensus of $(0.24) and sales of $136.49 million, beating the consensus of $134.07 million.
- For FY23, the company expects Nuplazid sales of $520-$550 million compared to a consensus of $569.16 million.
- Raymond James, maintaining a Market Perform rating, writes that 2023 revenue guidance does not include potential contributions from trofinetide, with a PDUFA date of March 12 for Rett Syndrome. The analyst projects around $14.5 million in trofinetide revenues in 2023.
- Given the lack of treatment options for Rett patients, if approved, there may be strong early demand for trofinetide. However, a high attrition rate is expected, given its AE profile and modest benefits.
- Beyond Rett, ACP-204 (next-generation pimavanserin) is exciting but awaits de-risking data before attributing value to the asset.
- Needham writes that while the management sees signs of stabilization in the PDP market, it is not yet seeing definitive signs of recovery. The analyst expects the lower-than-expected Nuplazid guidance to drive some weakness in the stock.
- Overall, it remains on the sidelines to foresee limited upside vs. cons. for Nuplazid sales in the near term and trofinetide launch.
- The analyst keeps a Hold rating.
- Cantor Fitzgerald reiterates its Overweight rating and increases the price target to $28 from $27.
- The analyst is optimistic about the revenue beat following the 3Q22 miss, with new patient adds in long-term care facilities on a vector to returning to pre-pandemic levels.
- The analyst also notes recent publications pointing to real-world evidence supporting Nuplazid's differentiated clinical profile, which might provide modest but steady sales growth in 2023.
- Price Action: ACAD shares are up 10.72% at $21.48 on the last check Tuesday.
ACADACADIA Pharmaceuticals Inc
$16.75-0.15%
Edge Rankings
Momentum39.12
Growth79.91
Quality-
Value56.64
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
